On January 4, 2025, the 2024 TTM Capital Summit was successfully held at Taizhou International Jinling Hotel. The theme of this summit is "Gathering ecological forces and bridging industrial innovation", aiming to build a platform for exchanges and cooperation for industry leaders and partners from various fields. Besides, to explore the future development trend of the healthcare industry together.

Nearly 200 distinguished guests were invited to the summit. Among the participants are many academicians and leaders, nearly 50 investors, and more than 100 industry elites and experts. Yangtze River Pharmaceutical Group, as the host of this summit, provides the conference venue and gives strong support to TTM Capital. Haoyu Xu, Chairman of Yangtze River Pharmaceutical Group, personally delivered the opening speech for 2024 TTM Capital Summit.

Chairman of Yangtze River Pharmaceutical Group, Haoyu Xu

Later, the summit focused on the topics of medical ecology and industrial innovation. Through a series of insightful keynote speeches and roundtable meetings, the summit is a forum of forwarding looking inspirations for the investment, eco-system and R&D, and industry trend.

Part 1

Insightful keynote reports share visions

One of the highlights of this summit is that many industry leaders have delivered multiple Insightful keynote speeches to the summit.

Academician Jiandong Jiang of the Chinese Academy of Engineering

Academician Jiandong Jiang of the Chinese Academy of Engineering delivered a keynote speech titled "The Way to Show the Big Picture of Science in China: Pharmacy". He expounded on the outstanding contributions and development trends of traditional Chinese medicine in the field of new drug innovation. He pointed out that Chinese scientists are already in a leading position in the world in the research field of molecular identification of plant compounds. At the same time, he expressed his expectation for further exploration and excavation of the treasure trove of traditional Chinese medicine.

Executive President of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), Ruilin Song

Ruilin Song, executive president of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), delivered a keynote speech on "High-quality Development and Prospects of Pharmaceutical Innovation in China". He pointed out that the current medical system and medical insurance system have relatively serious suppression on the innovation. Basic medical insurance is challenging to support the development of the innovative drug market. Only through commercial insurance collaborative protection and multi-dimensional promotion of market policy reform can resolve the dilemma. At the same time, in the future, it is necessary to open up multiple payment channels and support commercial insurance. It is expected that in 2025, innovative drugs will have more development opportunities.

Foreign academician of the RAE, Dan Zhang

Dr. Dan Zhang, an overseas academician of the RAE, emphasized that the drug research and development strategy in the new environment urgently needs iteration. The clinical efficiency in China is as high as 15 times that of the United States. There are abundant patient resources. Moreover, national policies strongly support various new technologies such as cell therapy and new drug molecules. With the help of of clinical CROs, it is expected to sort out high-quality drug varieties and promote them to the international market.

Shanghai GoBroad Cancer Hospital, Jin Li

President Jin Li of GoBroad Cancer Hospital gave a speech titled "Innovative R&D of Anti-tumor Drugs in China". Dr. Li first defined the main research and development direction of anti-tumor drugs in China, that is, focusing on solving the pain of patients and focusing on their needs. He pointed out that population aging has promoted the continuous growth of the biomedical market. At present, it is the golden age of biopharmaceutical. He called on the medical community to work together to jointly create a glorious chapter in biopharmaceuticals.

Part 2

Stick to the original purpose and start a new chapter of development

Lily Zhang, founding and managing partner of TTM Capital, introduced TTM's excellent performance in 2024 to the guests under the title of "Forge ahead with full strength, right at this moment", and looked forward to the development prospects in 2025.

Founding and managing partner of TTM Capital, Lily Zhang

At 2024, Chinese innovative drugs showed strong global strength, with rapid development and a concentrated explosion of achievements. Despite the challenging macro environment, TTM Capital has achieved stellar investment returns. TTM is determined to become a flagship pioneering type of VC in the Chinese investment field and continues to provide firm support and companionship to scientist entrepreneurs.

Under the leadership of this strategy, in 2024, TTM Capital successfully invested in several drug research and development companies founded by top global Chinese scientists. Looking forward to the new year, TTM will continue to carry out high-level investment as always, adhere to the strategic orientation of incubating Venture Capital, and together with investors and entrepreneurs to achieve complementary advantages and win-win cooperation.

Special advisor of TTM Capital and former head of global research and development of Sanofi, Yongjun Liu

Dr. Yongjun Liu, special advisor of TTM Capital and former head of global research and development of Sanofi, deeply analyzed the similarities and differences between Chinese and American pharmaceuticals in terms of project initiation, teams and strategies. He pointed out that China is full of innovative vitality and has high efficiency. It has a complete industrial chain and CRO support. There are many young talents and the future prospects are very broad. However, it is necessary to break through the molecular innovation model dominated by few experts and move towards a disease area innovation model led by senior scientists in disease fields based on science, and strengthen in-depth cooperation with university professors and capital. He is looking forward to China developing drugs worth more than 4 billion US dollars.

At the summit, TTM Capital introduced new members of the TTM Family to all the guests, including ALLYRNA founded by Professor Chuan He (a world-class expert in RNA post-transcriptional modification, academician of the American Academy of Arts and Sciences, and winner of the Wolf Prize); PROSPECT founded by Dr. Shuhui Chen (former chief scientist of WuXi PharmaTech); RAYTHERA founded by Dr. Qing Dong (former chief scientist of Hengrui Pharmaceuticals and a successful serial entrepreneur); and Lead Healthcare, a key transformation project of Guangzhou Laboratory's academician team. In the project award session, the founders of these projects, Professor Chuan He, Dr. Shuhui Chen, and Dr. Qing Dong respectively recorded videos for the summit, narrated the process of getting connected with TTM and expressed their deep collaboration expectations for TTM. Feng Zhang, the founder of Lead Healthcare, made a speech, introduced the company's development status and expressed deep gratitude to the TTM team for the strong support.

2024 Special Feature of TTM Invested Enterprises

Part 3

Elite gathered at roundtable and discussed industry trends

The two brainstorming sessions in this summit are hosted by Eric Chai and Haiding Yang, partners of TTM Capital.

Roundtable themed on "Investment is an art of mutual empowerment and achievement"

In the morning meeting, Dr. Eric Chai, partner of TTM Capital, hosted a roundtable on the theme of "Investment is an art of mutual empowerment and achievement."Yerong Xu, vice president of Shanghai State-owned Capital Investment, Chunguang Liu, managing partner of Tailong Venture Capital, Ao Zhang, director of the School of Pharmacy of Shanghai Jiao Tong University, Yanan Xu, head of China region of Takeda Pharmaceutical's global external innovation cooperation department, and Ming Xu, chief operating officer of Ablaze Pharmaceuticals, jointly discussed the topic of how LP, GP, and founders can achieve mutual success during the recession period of biomedicine.

Roundtable themed on "Finding the Second Growth Curve: BD, Going Global and Newco

The afternoon brainstorming session revolved around the recent hot topic "Finding the Second Growth Curve: BD, Going Global and Newco". Host Haiding Yang, partner of TTM Capital, and Jinhua Zhang, founder of IASO Bio, Jiguo Zhang, president of the vaccine business unit of Fosun Pharma, Jiazhen Chen of external innovation of BioNTech, Yanci Sheng, general manager of global strategic projects of Henlius, and Han Dai, chief innovation officer of Viva Biotech elaborated on the strategic considerations of their respective enterprises in the global layout, deeply analyzed the business logic behind it, and discussed various exit models of Chinese innovative drugs under this new situation.

Part 4

Yangtze River Pharmaceutical Group delivered concluding keynote

A special session of this summit is the special report prepared by Yangtze River Pharmaceutical Group, followed by the visit to the exhibition area.

President of Yangtze River Pharmaceutical Group Research Institute: Ruwei Wang

Dr. Ruwei Wang, special assistant to the chairman, chief scientist and president of the research institute of Yangtze River Pharmaceutical Group, delivered a speech entitled "Attracting valuable enterprise, lead the ecology and empower the positive development of the industrial chain". He introduced the strategic layout of Yangtze River Pharmaceutical Group in leading the ecology and empowering the healthy development of the industrial chain. At the same time, he expounded on the development history of Yangtze River Pharmaceutical Group, the development plan of the healthcare industry, the commercial concept of healthy marketing and marketing health, and the wish of Yangtze River Pharmaceutical Group to create high-quality development and build the strongest ecosystem with industry as the core and empower ecological development.

Following Dr. Ruwei Wang’s report, Yangtze River Pharmaceutical Group also provided the guests of this summit with an opportunity to visit their factory area, starting a journey to explore the connection among industry medical innovation and healthcare ecosystem. This is not only a visiting activity, but also an opportunity for in-depth understanding and communication, allowing the guests to personally feel the corporate culture, innovative spirit and unique corporate atmosphere of Yangtze River Pharmaceutical Group.

Concluding

With the successful conclusion of the 2024 TTM Capital Summit, with the theme of "Gathering Ecological Forces and Bridging Industrial Innovation", we have witnessed ideas and wisdom. TTM Capital, with its excellent resource integration ability, profound market insight and keen business intuition, has not only set a new benchmark in the industry, but also won the extensive recognition and trust of partners with the value orientation and concept of "Fusion with ingenuity and creativity, salvation with love and responsibility; Triumph in frontier exploration by trust and collaboration; Cross pollination and inspiration by sharing value and belief; Together to miracle with vision and perseverance".

Even though the path is filled with numerical challenges, through close collaboration with partners, TTM Capital believe that it is capable of creating more opportunities and bringing more vitality and innovation to the medical investment industry. TTM Capital will take on "Gathering ecological forces and bridging industrial innovation" as our own responsibility, and will start a new journey together hand by hand.

Who we are

TTM Capital is a professional investment institution focused on early-stage investments in the healthcare sector. The founding and managing team been involved in the medical and biotechnology fields for many years, with a background in medical investments from top domestic funds to full industry chain experience from globally leading multinational pharmaceutical companies.
TTM Capital mainly focuses on high-quality investment opportunities in the fields of biopharmaceuticals, medical devices and in vitro diagnostics driven by cutting-edge technology, focusing on segmented tracks with significant advantages, focusing on the global medical market and the "unmet needs" of patients. Persist in empowering and creating synergistic value for invested companies, jointly promote medical innovation, and create value for society.